4CPS-115 Nabpaclitaxel plus gemcitabine versus folfirinox in metastatic pancreatic cancer: real-world data experience | European Journal of Hospital Pharmacy

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Section 4: Clinical pharmacy services

4CPS-115 Nabpaclitaxel plus gemcitabine versus folfirinox in metastatic pancreatic cancer: real-world data experience

Free

Online download statistics by month:

Online download statistics by month: March 2022 to November 2024

	Abstract	Full	Pdf
Mar 2022	23	0	1
Apr 2022	26	0	1
May 2022	8	0	2
Jun 2022	14	0	1
Jul 2022	32	0	3
Aug 2022	12	0	2
Sep 2022	20	0	3
Oct 2022	29	0	1
Nov 2022	12	0	1
Dec 2022	19	0	1
Jan 2023	16	0	1
Feb 2023	7	0	2
Mar 2023	5	0	0
Apr 2023	6	0	0
May 2023	2	0	0
Jul 2023	6	0	3
Sep 2023	4	0	0
Oct 2023	2	0	1
Nov 2023	13	0	1
Dec 2023	8	0	0
Jan 2024	3	0	2
Feb 2024	8	0	2
Mar 2024	6	0	2
Apr 2024	4	0	2
May 2024	11	0	1
Jun 2024	2	0	2
Jul 2024	5	0	2
Aug 2024	2	0	2
Sep 2024	20	0	0
Oct 2024	6	0	0
Nov 2024	7	0	2
Total	338	0	41